XTuit Believes Microenvironment Approach Will Yield Cancer And Fibrosis Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Coming out of stealth with a $22 million Series A round, the biotech thinks its therapies targeting abnormal stroma could improve the activity of checkpoint inhibitors in cancer combo therapy and possibly reverse fibrosis in advanced liver disease.